



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Bae Abertawe
Swansea Bay University
Health Board

Cadeirydd Dros Dro/ Interim Chair: **Emma Woollett**
Prif Weithredwr/Chief Executive: **Tracy Myhill**

gofalu am ein gilydd, cydweithio, gwella bob amser
caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome
correspondence in Welsh or English.

Dyddiad/Date: 28th February 2020
Ein Cyf / Our Ref: 20-B-017

☎ 01639 [REDACTED]

📧 FOIA.Requests@wales.nhs.uk

Corporate Services
Headquarters
1 Talbot Gateway
Baglan
Port Talbot, SA12 7BR

[REDACTED]
[REDACTED]

[REDACTED]

I refer to your Freedom of Information Act Request acknowledged by ourselves on
12th February 2020. Your request sought information relating to Adalimumab.

Question 1

	Rheumatology	Dermatology	Gastroenterology
Is the branded biosimilar AMGEVITA listed on your formulary?	Y	Y	Y

Question 2

Please complete the number of patients prescribed with the following products in the last 12 months within the Rheumatology, Dermatology and Gastroenterology departments:

Please note that the figures we have provided are the totals for the speciality and product. We are not able to provide first or second line use as this is held within individual patient notes. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

Product/place in the Adalimumab therapy pathway*	Rheumatology	Dermatology	Gastroenterology
AMGEVITA	0	70	78
HUMIRA	74	8	19
HYRIMOZ	0	0	0
IMRALDI	360	9	0

***How many patients receive the listed therapies as a first or second treatment once they reach the biologic/biosimilar part of their treatment pathway? For example, according to the NICE Pathway, psoriasis patients should receive topical therapy, then systemic non-biological therapy, then systemic biological therapy. We would like to know which therapies are received first and second in the biological therapy part of the pathway.**

Question 3

Please complete the table below:

		Are any local guidelines followed that recommend earlier use of anti-TNF biologics/biosimilars in the treatment pathway?	Are there occasions where patients can receive Adalimumab outside of NICE /SMC /AWMSG /National criteria?
Dermatology	Psoriasis	Y	Y
Rheumatology	Psoriatic arthritis	N	Y
	Rheumatoid arthritis	N	Y
	Ankylosing Spondylitis	N	Y
Gastroenterology	Crohn's disease	N	Y
	Ulcerative colitis	N	Y



Question 4

What is the contractual agreement for seeing and treating patients with anti-TNF biologics between you and your referring CCGs/Health Boards?

Not applicable within NHS Wales Health Boards. Swansea Bay Health Board are not commissioned to treat patients.

I hope this information is helpful. If you require anything further please contact us at FOIA.Requests@wales.nhs.uk.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via FOIA.Requests@wales.nhs.uk.

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



Pam Wenger
Director of Corporate Governance

